Display options
Cite
Zhang C, Wang S, Israel HP, et al. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus. 2015;4:386doi: 10.1186/s40064-015-1116-2.
Zhang, C., Wang, S., Israel, H. P., Yan, S. X., Horowitz, D. P., Crockford, S., Gidea-Addeo, D., Clifford Chao, K. S., Kalinsky, K., & Connolly, E. P. (2015). Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. SpringerPlus, 4386. https://doi.org/10.1186/s40064-015-1116-2
Zhang, Chi, et al. "Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy." SpringerPlus vol. 4 (2015): 386. doi: https://doi.org/10.1186/s40064-015-1116-2
Zhang C, Wang S, Israel HP, Yan SX, Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky K, Connolly EP. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. Springerplus. 2015 Jul 30;4:386. doi: 10.1186/s40064-015-1116-2. eCollection 2015. PMID: 26240784; PMCID: PMC4519490.
Copy Download .nbib Format: NLM
Share it on

Springerplus. 2015 Jul 30;4:386. doi: 10.1186/s40064-015-1116-2. eCollection 2015.

Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy.

SpringerPlus

Chi Zhang, Shuang Wang, Hayley P Israel, Sherry X Yan, David P Horowitz, Seth Crockford, Daniela Gidea-Addeo, K S Clifford Chao, Kevin Kalinsky, Eileen P Connolly

Affiliations

  1. Department of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY USA.
  2. Department of Biostatistics, Columbia University School of Medicine, New York, NY USA.
  3. Columbia University School of Medicine, New York, NY USA.
  4. Department of Medical Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY USA.

PMID: 26240784 PMCID: PMC4519490 DOI: 10.1186/s40064-015-1116-2

Abstract

BACKGROUND: Breast cancer subtype, determined by expression of estrogen/progesterone receptor (ER/PR) and human epidermal growth factor receptor (HER)-2, is predictive for prognosis. The importance of subtype to locoregional recurrence (LRR) following neoadjuvant chemotherapy (NAC) is unknown, particularly after adjuvant radiotherapy (RT).

METHODS: We retrospectively identified 160-breast cancer patients registered at Columbia University Medical Center from 1999 to 2012 treated with NAC, surgery and adjuvant RT.

RESULTS: Patients were grouped by receptor status: hormone receptor positive (HR+) [(ER or PR+)/HER2-; n = 75], HER2+ (n = 46), or triple-negative (TNBC) [ER (-) PR (-) HER2 (-); n = 36]. The median follow-up was 28 months. 92.0% received an anthracycline-taxane based NAC and 80.4% of HER2+ patients received trastuzumab. All underwent surgical resection followed by RT. 15.6% had a pathologic complete response (pCR): 26% of HER2+, 5% of HR+, and 25% of TN. The actuarial rate of DM was 13.8% for the entire cohort, with equivalent rates by subtypes in non-pCR patients. The overall rate of LRR was 8%. However, the LRR rate was significantly higher for TNBC patients (22.2%) than HER2+ (5.6%) (p = 0.025) or HR+ (3.0%) (p = 0.037) in non-pCR group. In the pCR group, two patients had recurrence; one LRR and one a DM, both had TNBC. All LRR occurred in or near the radiation field.

CONCLUSIONS: TNBC patients with < pCR to NAC have a significantly higher LRR rate as compared to other subtypes even with surgery and adjuvant RT. Our data support a need to further intensify local therapy in TNBC patients.

Keywords: Locoregional recurrence rate; Neoadjuvant chemotherapy; Radiation; Triple-negative breast cancer

References

  1. Breast Cancer Res Treat. 2011 Aug;128(3):899-906 - PubMed
  2. J Clin Oncol. 2014 Feb 20;32(6):494-5 - PubMed
  3. PLoS One. 2013 Oct 22;8(10 ):e78259 - PubMed
  4. J Womens Health (Larchmt). 2009 Jun;18(6):883-93 - PubMed
  5. J Clin Invest. 2011 Jul;121(7):2750-67 - PubMed
  6. JAMA. 2006 Apr 12;295(14):1658-67 - PubMed
  7. Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12 - PubMed
  8. Clin Cancer Res. 2004 Aug 15;10(16):5367-74 - PubMed
  9. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
  10. Breast Cancer Res. 2012 May 23;14(3):R83 - PubMed
  11. Clin Cancer Res. 2007 Apr 15;13(8):2329-34 - PubMed
  12. Breast Cancer Res. 2012 May 23;14(3):R82 - PubMed
  13. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002 - PubMed
  14. Breast Cancer Res Treat. 2012 Apr;132(3):1049-62 - PubMed
  15. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 - PubMed
  16. J Clin Oncol. 2008 May 20;26(15):2568-81 - PubMed
  17. J Clin Oncol. 2008 Mar 10;26(8):1275-81 - PubMed
  18. J Clin Oncol. 2006 Dec 20;24(36):5652-7 - PubMed
  19. J Clin Oncol. 2009 Mar 10;27(8):1168-76 - PubMed
  20. Ann Surg Oncol. 2013 Jan;20(1):87-93 - PubMed
  21. Womens Health (Lond). 2011 Nov;7(6):677-87 - PubMed
  22. Ann Surg Oncol. 2011 Oct;18(10):2851-7 - PubMed
  23. J Clin Oncol. 2012 May 20;30(15):1796-804 - PubMed
  24. Clin Breast Cancer. 2013 Oct;13(5):335-43 - PubMed
  25. J Clin Oncol. 2008 May 10;26(14):2373-8 - PubMed
  26. Cancer. 2007 May 1;109(9):1721-8 - PubMed
  27. Breast Cancer Res Treat. 2009 Jan;113(2):357-70 - PubMed
  28. Arch Pathol Lab Med. 2010 Jul;134(7):e48-72 - PubMed
  29. J Clin Oncol. 2009 Oct 1;27(28):4701-8 - PubMed
  30. J Clin Oncol. 2008 Feb 10;26(5):778-85 - PubMed
  31. Clin Cancer Res. 2005 Aug 15;11(16):5678-85 - PubMed
  32. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34 - PubMed
  33. Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 - PubMed
  34. J Clin Oncol. 2011 Jul 20;29(21):2852-8 - PubMed
  35. Breast Cancer Res. 2013;15(5):R77 - PubMed
  36. JAMA. 2006 Jun 7;295(21):2492-502 - PubMed

Publication Types

Grant support